Market closedNon-fractional

ADC Therapeutics/ADCT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About ADC Therapeutics

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Ticker

ADCT

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology

Headquarters

Epalinges, Switzerland

Employees

274

ADC Therapeutics Metrics

BasicAdvanced
$314M
Market cap
-
P/E ratio
-$2.77
EPS
1.62
Beta
-
Dividend rate
$314M
1.62
4.608
4.088
-222.632
-223.369
-3.08%
-24.08%
289.97%
3.903
-1.39
-1.39
-1.784
-62.38%
9.58%
-7.88%

What the Analysts think about ADC Therapeutics

Analyst Ratings

Majority rating from 7 analysts.
Buy

ADC Therapeutics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-258.88% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$18M
-74.10%
Net income
-$47M
-80.58%
Profit margin
-258.88%
-25.03%

ADC Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0.78%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.58
-$0.58
-$1.03
-$0.56
-
Expected
-$0.46
-$0.63
-$0.50
-$0.56
-$0.44
Surprise
26.87%
-8.55%
104.77%
0.78%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for ADC Therapeutics stock?

ADC Therapeutics (ADCT) has a market cap of $314M as of July 06, 2024.

What is the P/E ratio for ADC Therapeutics stock?

The price to earnings (P/E) ratio for ADC Therapeutics (ADCT) stock is 0 as of July 06, 2024.

Does ADC Therapeutics stock pay dividends?

No, ADC Therapeutics (ADCT) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next ADC Therapeutics dividend payment date?

ADC Therapeutics (ADCT) stock does not pay dividends to its shareholders.

What is the beta indicator for ADC Therapeutics?

ADC Therapeutics (ADCT) has a beta rating of 1.62. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell ADC Therapeutics stock

Buy or sell ADC Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing